Physician profile
Prafull Dave
NPI 1326008582
$11,977.63
in general payments reported to CMS, 2019-2025
62 companies · $2,133 in 2025
The $2,133 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,169 · 2020: $1,147 · 2021: $1,703 · 2022: $2,200 · 2023: $1,718 · 2024: $1,906 · 2025: $2,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,728 · Education: $29.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,728.40 |
| Education | $29.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,694.43 | 2019-2025 | |
| Abbvie INC. | $1,320.44 | 2019-2025 | Vraylar, Ubrelvy, Duopa |
| Supernus Pharmaceuticals, INC. | $1,020.18 | 2019-2025 | Qelbree, Oxtellar Xr |
| Lilly USA, LLC | $933.63 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Eisai INC. | $628.16 | 2019-2025 | |
| Lundbeck LLC | $602.61 | 2019-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $543.98 | 2019-2025 | Mavenclad |
| Celgene Corporation | $438.37 | 2021-2025 | Zeposia |
| Ucb, INC. | $371.45 | 2019-2025 | Rystiggo, Briviact |
| Genzyme Corporation | $283.38 | 2019-2022 | |
| Biogen, INC. | $270.05 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Harmony Biosciences LLC | $258.81 | 2020-2025 | Wakix |
| Teva Pharmaceuticals USA, INC. | $245.40 | 2019-2025 | Austedo Xr, Austedo Xr |
| Neurelis, INC. | $238.68 | 2020-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $227.93 | 2019-2025 | Ultomiris, Koselugo |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prafull Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.